Dow University of Health Sciences

Firas A. Adeel, MD is recognized by Continental Who's Who

Retrieved on: 
Tuesday, May 10, 2022
ABIM, University, Music, American Board of Internal Medicine, OH, Chronic kidney disease, Bass, Physician, MBBS, American Society of Nephrology, Patient, Loving Memory, Anderson, Family, Dow University of Health Sciences, Ministry of Health (New South Wales), Outline of health sciences, Dialysis, Kidney failure, MD, Internal medicine, National Kidney Foundation, Continental, Society, Fellow, Kidney, Sodium, American Board of Commissioners for Foreign Missions, Multimedia, Medicine, Dentistry, Nephrology

CINCINNATI, May 9, 2022 /PRNewswire/ -- Firas A. Adeel, MD, is being recognized by Continental Who's Who as a Top Pinnacle Nephrologist in the Medical field and in acknowledgment of his work at Mt.

Key Points: 
  • CINCINNATI, May 9, 2022 /PRNewswire/ -- Firas A. Adeel, MD, is being recognized by Continental Who's Who as a Top Pinnacle Nephrologist in the Medical field and in acknowledgment of his work at Mt.
  • Auburn Nephrology Inc.
    Firas A. Adeel, MD, has six years of experience and currently treats patients at Mt.
  • Dr. Adeel administers dialysis, advocates for home dialysis care, and oversees medical management for kidney transplant patients.
  • He provides personalized treatment plans for his patients, often including medication, specific types of diets, kidney transplants, and dialysis treatments.

Bexson Biomedical Announces Publication of Peer Reviewed Article Describing Novel Ketamine Formulation

Retrieved on: 
Wednesday, March 16, 2022
Doctor of Philosophy, MD, PH, Technology, University, Patient, Ketamine, Dow University of Health Sciences, Pain, Multimedia, Skin, Opioid, Excipient, Company, Tissue, Subcutaneous tissue, Research, Bird, NMDA, MDPI, Science, Pain management, Pharmaceutical industry

SANTA BARBARA, Calif., March 16, 2022 /PRNewswire/ --Bexson Biomedical, Inc., a company developing subcutaneously delivered therapies for pain management, addiction and mental health disorders, announced today the publication of a peer-reviewed paper in MDPI describing the company's novel formulation technology, applied to ketamine.

Key Points: 
  • SANTA BARBARA, Calif., March 16, 2022 /PRNewswire/ --Bexson Biomedical, Inc., a company developing subcutaneously delivered therapies for pain management, addiction and mental health disorders, announced today the publication of a peer-reviewed paper in MDPI describing the company's novel formulation technology, applied to ketamine.
  • The article, Three Birds, One Excipient ,was co-authored by Jason Wallach, James Gamrat, Rebekah Jauhola-Straight, Jeffrey Becker, and Thomas Eckrich.
  • The research describesthe development of Bexson Biomedical'snovel technologydesigned to optimize the pH and osmolality of drug solutions for subcutaneous delivery.
  • Bexson Biomedical, Inc. is a research stage company developing BB106, a ketamine therapy for pain management and mental health disorders.

Treatment for Critically Ill COVID Patients Begins 1st Randomized Clinical Trial

Retrieved on: 
Tuesday, August 31, 2021
Research, Medical Devices, Medical Supplies, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Jean-Louis Vincent, Sepsis, COVID, Blood, Enrollment, Virus, Physician, Communication, Survival, Infection, Observational study, Bacteria, Fungus, Pandemic, Person, Research, Food, Uniformed Services University of the Health Sciences, Henry M. Jackson Foundation for the Advancement of Military Medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Outline of health sciences, EUA, Septic shock, Hospital, ICU, USU, Mortality, Safety, Heparin, Survival rate, News, Patient, Septic, Dow University of Health Sciences, IDE, DARPA, FDA, COVID-19, Military medicine, Pharmaceutical industry, Risk management, ExThera Medical Corporation, Seraph 100, EXTHERA MEDICAL CORPORATION, SERAPH 100

The first multicenter randomized controlled trial of the Seraph 100, which has successfully treated hundreds of COVID patients, will be studying the treatments ability to reduce ICU length of stay, hospital duration and mortality in patients suffering from septic shock..

Key Points: 
  • The first multicenter randomized controlled trial of the Seraph 100, which has successfully treated hundreds of COVID patients, will be studying the treatments ability to reduce ICU length of stay, hospital duration and mortality in patients suffering from septic shock..
  • The initial findings in our observational study for COVID patients have been very promising.
  • The study will evaluate the safety and efficacy of pathogen-removing extracorporeal blood purification therapy in critically ill patients with pathogen-associated shock utilizing ExTheras Seraph 100 filter.
  • ExThera Medicals extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from severe infections.